Veracyte Inc. Unveils Promising Data from Decipher Portfolio at AUA 2026

Veracyte, Inc. (Nasdaq: VCYT), a trailblazer in cancer diagnostics, has announced an impressive array of more than 15 studies related to its Decipher portfolio, set to be presented at the upcoming American Urological Association (AUA) Annual Meeting from May 15-18, 2026, in Washington, D.C. This data underscores the growing significance of the Decipher Bladder and Prostate tests in delivering personalized care for patients with urologic cancers.

The studies presented will provide vital insights into molecular subtypes tied to patient outcomes in bladder cancer and will feature large-scale real-world data analyses in prostate cancer. These findings are expected to illuminate how the Decipher Prostate test is reshaping treatment decisions, thereby enhancing patient care.

Elai Davicioni, Ph.D., Veracyte’s medical director for Urology, remarked, “These studies underscore the power of Veracyte’s Diagnostics Platform to generate clinically meaningful evidence at scale.” He noted that with more than a decade's worth of data from the Decipher GRID tool, Veracyte is poised to accelerate research that drives new discoveries, helping clinicians to better personalize care and improve patient outcomes.

In recognition of Bladder Cancer Awareness Month, several key studies will focus on the clinical relevance of molecular subtyping in bladder cancer through the Decipher Bladder test. These studies aim to refine risk stratification, identify subsets of patients with varying clinical outcomes, and enhance understanding of tumor biology. Notable presentations include:

Dr. Shilpa Gupta highlighted the importance of these findings, stating, “These data suggest that molecular subtyping using Decipher Bladder may help identify patients who are more likely to achieve downstaging and complete responses to neoadjuvant chemo-immunotherapy.”

Veracyte is also showcasing significant analyses from the Decipher Prostate test, which harnesses genomic data and real-world clinical datasets to inform personalized treatment decisions in prostate cancer. Key presentations include:

Dr. Leapman stated, “Decipher GRID enables analyses that were not previously possible,” underscoring the test's ability to facilitate individualized management of prostate cancer.

Veracyte is committed to transforming cancer care through its innovative Veracyte Diagnostics Platform, which integrates extensive genomic and clinical data with advanced bioinformatics and AI capabilities. The Decipher tests, including Decipher Prostate and Decipher Bladder, are designed to provide actionable insights that can significantly influence treatment pathways.

As Veracyte prepares for its presence at AUA 2026, the company continues to lead the way in cancer diagnostics, showcasing its commitment to improving outcomes for patients through personalized care strategies. The wealth of data from the Decipher portfolio is set to impact the future of urologic cancer management significantly. For more insights, attendees can visit Veracyte’s booth #3405 during the conference.